Drugs manufacturer Shield Therapeutics widened losses to £11.8m in the first half of the year, but has hailed progress in its key US market.
The listed pharmaceuticals firm, which has a base on Gateshead Quays, reported higher revenue of £2m in the period as it said there was growing momentum behind prescriptions of its flagship iron deficiency product in the US. One year on from the Stateside launch of Accrufer, Shield pointed to a 350% increase in prescriptions to 11,223 among GPs and women's health specialists.
In carrying out its US commercial strategy and launch plan, Shield said it had introduced more than 1,000 first time prescribers of Accrufer tablets and 2,300 healthcare providers had participated in its sponsored programmes. And in Europe, sales of its drugs - marketed as Feraccru - were 15% higher compared to the first half of 2021.
